PRESERVE II研究:Zenith髂动脉分支移植物五年结局
PRESERVE II是一项前瞻性、非随机、单臂、多中心研究,纳入40例适合腔内修复的主动脉髂或髂动脉瘤患者,评估Zenith髂动脉分支移植物联合iCast覆膜支架的安全性和有效性。结果显示6个月免于通畅性相关干预为100%,5年全因死亡率为88.9%,无动脉瘤相关死亡,支持该技术长期安全有效并维持髂内动脉灌注。
要点
- 6个月免于通畅性相关干预为100%,6个月分支血管通畅率为100%。
- 5年全因死亡率为88.9%,无动脉瘤相关死亡,无破裂或III型内漏。
- 随访期间发生4例ZBIS相关闭塞,4例患者需6次二次干预。
核心结论
- PRESERVE II研究达到主要和次要终点性能目标,且表现高于预期目标。
- 长期结局支持ZBIS联合iCast覆膜支架在EVAR中维持髂内动脉灌注的持续安全性和有效性。
研究设计与样本
- 前瞻性、非随机、单臂、多中心临床研究,在美国18个中心开展。
- 2014至2015年纳入40例适合腔内修复的主动脉髂或髂动脉瘤患者,随访至5年。
主要发现
- 技术成功率为100%,6个月免于通畅性相关干预为100%(39/39),30天免于并发症为85%(34/40),6个月分支血管通畅率为100%(37/37)。
- 随访期间10例患者发生主要并发症,包括需干预的心脏事件(n=1)、肠梗阻(n=1)、腿缺血(n=1)、卒中(n=2)、ZBIS同侧臀部跛行(n=1)和阳痿(n=5)。
- 5年随访 available 75%(30/40),完整影像学 available 86.7%(26/30);5年全因死亡率为88.9%,无动脉瘤相关死亡。
- 随访期间发生4例ZBIS相关闭塞(髂外动脉段2例,髂内动脉段2例),4例患者需6次ZBIS相关二次干预。
- 5年时髂动脉瘤尺寸缩小占26.9%(7/26),不变占73.1%(19/26);记录到1例同侧髂动脉瘤增长(术后4年),与Ic型内漏相关。
临床怎么用
- 对于适合腔内修复的主动脉髂或髂动脉瘤患者,ZBIS联合iCast覆膜支架可维持髂内动脉灌注,且5年结果支持其安全性和有效性。
- 需关注ZBIS相关闭塞和二次干预风险,以及术后髂动脉瘤尺寸变化和内漏发生。
局限性
- 单臂、非随机设计,样本量较小(40例),随访5年时仅75%患者 available。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: PRESERVE II was an Investigational Device Exemption pivotal study performed to evaluate the safety and effectiveness of the Zenith Iliac Branch Graft (ZBIS) with the iCast covered stent system in patients with aortoiliac or iliac aneurysms having a morphology suitable for endovascular repair. METHODS: PRESERVE II was a prospective, nonrandomized, single-arm, multicenter, clinical study conducted among 18 sites in the United States. Patients were enrolled between 2014 and 2015, with follow-up to 5 years. The primary end point was 6-month freedom from patency-related interventions. Secondary end points were 30-day freedom from morbidity and 6-month branch vessel patency. RESULTS: Forty patients (95% male; mean age, 67.8 years) were treated; technical success was 100%. Six-month freedom from patency-related intervention was 100% (39/39), 30-day freedom from morbidity was 85% (34/40), and 6-month branch vessel patency was 100% (37/37). Major complications occurred in 10 patients through follow-up. These included a cardiac event requiring intervention (n = 1), ileus (n = 1), leg ischemia (n = 1), stroke (n = 2), buttock claudication ipsilateral to the ZBIS (n = 1), and impotence (n = 5). Five-year follow-up was available in 75% of patients (30/40), with complete imaging in 86.7% of available patients (26/30). Freedom from all-cause mortality at 5 years was 88.9%. There was no aneurysm-related mortality. There were four occlusions related to the ZBIS through follow-up: two in the external iliac artery segment and two in the internal iliac artery segment. In total, four patients required six secondary interventions related to the ZBIS device through 5 years. The treated iliac aneurysm size decreased in 26.9% of patients (7/26) and remained unchanged in 73.1% (19/26) at 5 years. A single case of ipsilateral iliac aneurysm growth was recorded at 4 years post procedure, associated with a type Ic endoleak. There were no ruptures, type III endoleaks, migrations, or device integrity issues. CONCLUSIONS: The results of the PRESERVE II study met its performance goals for both primary and secondary end points, with higher performance rates than the expected targets. Long-term outcomes support the sustained safety and effectiveness of the ZBIS in combination with the iCast covered stent to preserve hypogastric artery perfusion during endovascular aneurysm repair.
引用
- Lee WA, Mantese V, Lee JT, et al. Five-year outcomes of the PRESERVE II Zenith iliac branch pivotal clinical study. J Vasc Surg. 2025. PMID: 41067585. doi:10.1016/j.jvs.2025.09.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。